J Saldanha1, N Lelie, A Heath. 1. Division of Virology, National Institute for Biological Standards and Control, South Mimms, UK. jsaldanha@nibsc.ac.uk
Abstract
BACKGROUND AND OBJECTIVES: The aims of this study were the establishment of a WHO International standard for HCV RNA for nucleic acid amplification technology (NAT) assays and the determination of the HCV RNA content of the candidate standard. MATERIALS AND METHODS: Twenty-two laboratories evaluated three candidate materials (two lyophilised, AA and BB, which were derived from the same source and one a liquid preparation, CC). All samples were HCV genotype 1 with a concentration of approximately 10(5) genome equivalents/ml. The methods used included the Roche Amplicor assay (version 1), Chiron Quantiplex (bDNA) assay, Organon Teknika NASBA assay, Transcription Mediated assay and various in-house assays, using single or nested primers. RESULTS: There was reasonable agreement between the overall mean NAT detectable units/ml obtained by the different assays except for some of the in-house assays using single primers which gave substantially lower estimates. These titres were 5.0 log10 for samples AA and BB and 4.6 log10 for sample CC. CONCLUSIONS: Sample AA was accepted as the candidate standard and assigned a titre of 10(5) international units (IU)/ml. The International Standard consists of a batch of vials each containing 50,000 IU/vial. Preliminary studies indicated that the material is stable at +4 degrees C and +20 degrees C for up to 200 days.
RCT Entities:
BACKGROUND AND OBJECTIVES: The aims of this study were the establishment of a WHO International standard for HCV RNA for nucleic acid amplification technology (NAT) assays and the determination of the HCV RNA content of the candidate standard. MATERIALS AND METHODS: Twenty-two laboratories evaluated three candidate materials (two lyophilised, AA and BB, which were derived from the same source and one a liquid preparation, CC). All samples were HCV genotype 1 with a concentration of approximately 10(5) genome equivalents/ml. The methods used included the Roche Amplicor assay (version 1), Chiron Quantiplex (bDNA) assay, Organon Teknika NASBA assay, Transcription Mediated assay and various in-house assays, using single or nested primers. RESULTS: There was reasonable agreement between the overall mean NAT detectable units/ml obtained by the different assays except for some of the in-house assays using single primers which gave substantially lower estimates. These titres were 5.0 log10 for samples AA and BB and 4.6 log10 for sample CC. CONCLUSIONS: Sample AA was accepted as the candidate standard and assigned a titre of 10(5) international units (IU)/ml. The International Standard consists of a batch of vials each containing 50,000 IU/vial. Preliminary studies indicated that the material is stable at +4 degrees C and +20 degrees C for up to 200 days.
Authors: Peter E Barker; Michael S Watson; John R Ticehurst; Jennifer C Colbert; Catherine D O'Connell Journal: J Clin Lab Anal Date: 2002 Impact factor: 2.352
Authors: Eric C J Claas; Marco W Schilham; Caroline S de Brouwer; Petr Hubacek; Marcela Echavarria; Arjan C Lankester; Maarten J D van Tol; Aloys C M Kroes Journal: J Clin Microbiol Date: 2005-04 Impact factor: 5.948
Authors: Roberta M Madej; Jack Davis; Marcia J Holden; Stan Kwang; Emmanuel Labourier; George J Schneider Journal: J Mol Diagn Date: 2010-01-14 Impact factor: 5.568
Authors: R T Hayden; K M Hokanson; S B Pounds; M J Bankowski; S W Belzer; J Carr; D Diorio; M S Forman; Y Joshi; D Hillyard; R L Hodinka; M N Nikiforova; C A Romain; J Stevenson; A Valsamakis; H H Balfour Journal: J Clin Microbiol Date: 2007-11-07 Impact factor: 5.948